Connect with us

Technology

CPC Biotech Introduces One-Inch Flow Path, Single-Use Sterile Disconnect for Bioprocessing

Published

2 hours ago

on

DOWNERS GROVE, Ill., July 15, 2026 /PRNewswire/ — CPC Biotech, part of PSG and Dover (NYSE: DOV) and a leading manufacturer of connectors, pumps, and flow sensors used in biopharmaceutical processing, today announced the launch of the RevolveSD™ Series. The new one-inch, single-use product enables sterile disconnection of bioprocess tubing in fewer steps than traditional methods that rely on clamps or sealers. RevolveSD disconnects allow bioprocessors to complete sterile disconnections in seconds, while also reducing setup time.

“We created RevolveSD connectors to simplify sterile disconnection in biopharmaceutical processes,” said Spencer Juola, product manager, CPC Biotech. “Operators can disconnect tubing without special equipment, and as a true one-time disconnect, this product helps prevent unintended reconnection and the associated risks of process sterility breaches.”

The RevolveSD Series is made of durable, lightweight polyphenylsulfone (PPSU), which is compatible with harsh chemicals used in applications such as antibody drug conjugate manufacturing. Its metal-free construction also eliminates corrosion risks in the flow path.

The RevolveSD Series features dual-valve, non-spill technology that minimizes residual fluid on the external valve face after disconnection. Its one-inch flow path size and valve design support smooth, bidirectional flow, minimizing turbulence and restriction.

“The RevolveSD Series addresses a real industry need for a high-flow disconnect that is sterile, single-use, and incredibly easy to use, according to early customer feedback,” Juola continued. “As the makers of AseptiQuik Series connectors, we have a long history of providing bioprocessors with robust solutions that meet demanding performance requirements. The RevolveSD Series builds on that expertise by bringing new efficiencies to large-scale bioprocessing, streamlining fluid disconnections and reducing tear-down complexities.”

For more information about the performance and versatility of the RevolveSD Series, please visit the CPC Biotech website. 

About CPC Biotech:

CPC Biotech is at the forefront of bioprocessing fluid management and flow control, offering a comprehensive portfolio of critical components: connectors, pumps, flow meters and sensors. Our industry-leading products permit biopharma innovators to produce next-generation biologics and therapeutics with optimal integrity, yield, efficiency and scalability. From lab to commercial launch, we enable those who drive breakthroughs in medicines and biologics that transform lives and advance humanity. CPC Biotech is part of Pump Solutions Group (PSG), an operating company within Dover Corporation. To learn more about CPC Biotech, please visit cpc-bio.com.

About PSG:

PSG is the global pump, metering, connector, and dispensing-solution expert, enabling the safe and efficient transfer of critical and valuable fluids that require optimal performance and reliability in applications where it matters most. Additionally, PSG is a leading provider of flow meters designed to reduce waste and downtime while accurately measuring, monitoring and controlling the distribution of fluids. Headquartered in Downers Grove, Illinois, USA, PSG is comprised of several world-class brands, including Abaque, All-Flo, Almatec, Blackmer, CPC Biotech, Cryo-Mach, Ebsray, em-tec, Griswold, Hydro, ipp, Malema, Mouvex, Neptune, Quantex, and Wilden. PSG products are manufactured on three continents – North America, Europe and Asia – in state-of-the-art facilities that practice lean manufacturing and are ISO-certified. PSG is part of the Pumps & Process Solutions segment of Dover Corporation. For additional information on PSG, please visit psgdover.com. PSG: Where Innovation Flows.

About Dover:

Dover is a diversified global manufacturer and solutions provider with annual revenue of over $8 billion. We deliver innovative equipment and components, consumable supplies, aftermarket parts, software and digital solutions, and support services through five operating segments: Engineered Products, Clean Energy & Fueling, Imaging & Identification, Pumps & Process Solutions and Climate & Sustainability Technologies. Dover combines global scale with operational agility to lead the markets we serve. Recognized for our entrepreneurial approach for over 70 years, our team of approximately 24,000 employees takes an ownership mindset, collaborating with customers to redefine what’s possible. Headquartered in Downers Grove, Illinois, Dover trades on the New York Stock Exchange under “DOV.” Additional information is available at dovercorporation.com.

CPC Biotech Contact:
Jana Stender
(612) 564-2053
jana.stender@cpc-bio.com

Dover Media Contact:
Adrian Sakowicz, VP, Communications
(630) 743-5039
asakowicz@dovercorp.com

Dover Investor Contact:
Jack Dickens, VP, Investor Relations
(630) 743-2566
jdickens@dovercorp.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cpc-biotech-introduces-one-inch-flow-path-single-use-sterile-disconnect-for-bioprocessing-302826616.html

SOURCE Dover

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment

Published

41 minutes ago

on

July 15, 2026

By

WASHINGTON, July 15, 2026 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant), the first new prescription medication approved for prevention of vomiting induced by motion in 47 years, will sponsor the No. 47 entry in the NTT IndyCar Series with Rahal Letterman Lanigan Racing.

The partnership aligns NEREUS’™ breakthrough innovation in motion relief with the high-speed world of IndyCar racing, where focus and stability are essential.

This sponsorship marks a symbolic milestone: 47 years since the last new motion sickness treatment was introduced in the United States. NEREUS™ represents a modern advancement as a selective NK-1 receptor antagonist designed to prevent vomiting induced by motion, offering a new option for millions who experience motion sickness during travel.

“Partnering with the No. 47 car perfectly captures this historic moment and our shared commitment to performance under challenging conditions,” said Mihael H. Polymeropoulos, M.D., President, CEO and Chairman of the Board of Vanda. 

The NEREUS™-branded No. 47 IndyCar will feature prominent sponsorship visibility across select NTT IndyCar Series events in 2026.

About NEREUS™ (tradipitant)

NEREUS™ is an oral NK-1 receptor antagonist FDA-approved for the prevention of vomiting induced by motion in adults. It is the first new pharmacologic treatment approved for this indication in over four decades.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

About Rahal Letterman Lanigan Racing

Rahal Letterman Lanigan Racing is a championship-winning team competing in the NTT IndyCar Series.

Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com 

Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com

Follow us on X @vandapharma

View original content to download multimedia:https://www.prnewswire.com/news-releases/nereus-powers-forward-sponsors-no-47-indycar-entry-celebrating-47-years-since-last-new-us-motion-sickness-treatment-302826721.html

SOURCE Vanda Pharmaceuticals Inc.

Continue Reading

Technology

VIAVI Announces Date for Fiscal Fourth Quarter and Fiscal Year 2026 Financial Results

Published

41 minutes ago

on

July 15, 2026

By

CHANDLER, Ariz., July 15, 2026 /PRNewswire/ — Viavi Solutions Inc. (VIAVI) (NASDAQ: VIAV) will announce its fiscal fourth quarter and fiscal year 2026 financial results for the period ended June 27, 2026, on Wednesday, August 5, 2026, after the close of market.

The Company will host an earnings call at 1:30 p.m. PT / 4:30 p.m. ET. A live webcast of the call and the replay will be available on the VIAVI website at https://investor.viavisolutions.com. The quarterly earnings press release, supplementary slides and historical financial tables will be posted under the “Quarterly Results” section.

To participate via telephone:

Toll-Free Dial-In Number:

1 (833) 461-5787

Toll Dial-In Number:

1 (585) 542-9983

Conference ID:

687 725 628

About VIAVI Solutions
VIAVI (NASDAQ: VIAV) is a global leader in test and measurement and optical technologies. Our test, monitoring, assurance, and resilient position, navigation and timing solutions enable and secure critical infrastructure ranging from data center ecosystems and communication networks to military, aerospace, railway and first responder communications. In addition, we develop and advance technologies used in high-volume optical applications across anti-counterfeiting, consumer electronics, aerospace, industrial and automotive end markets.

Learn more about VIAVI at www.viavisolutions.com. Follow us on VIAVI Perspectives, LinkedIn and YouTube.

Investors Contact:
Vibhuti Nayar, 408-404-6305; investor.relations@viavisolutions.com
Press Contact:
Amit Malhotra, 202-341-8624; amit.malhotra@viavisolutions.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/viavi-announces-date-for-fiscal-fourth-quarter-and-fiscal-year-2026-financial-results-302822275.html

SOURCE VIAVI Financials

Continue Reading

Technology

The American Council of the Blind to Distribute Ray-Ban Meta AI Glasses to Blind Veterans in St. Louis on July 27

Published

41 minutes ago

on

July 15, 2026

By

ALEXANDRIA, Va., July 15, 2026 /PRNewswire/ — The American Council of the Blind is proud to partner with Meta and the Blinded Veterans Association (BVA) to distribute Ray-Ban Meta AI glasses to eligible veterans who are blind during the upcoming 2026 ACB Conference and Convention in St. Louis.

The distribution will take place on Monday, July 27, from 1 to 5 p.m. CT at the Hyatt St. Louis at The Arch in downtown St. Louis. Eligible veterans can receive Ray-Ban Meta AI glasses at no cost while supplies last and a complimentary day pass to the ACB convention for July 27.

The initiative is part of Meta’s commitment to donate Ray-Ban Meta AI glasses to 130,000 blinded veterans worldwide, expanding access to technology that can support greater independence, access to information, and everyday tasks. As a distribution partner, ACB will also provide access to training resources for veterans receiving Meta glasses.

“Supporting veterans who are blind or have low vision has long been an important part of ACB’s mission,” said ACB Executive Director Scott Thornhill. “We are honored to partner with Meta and BVA to help connect veterans with innovative technology that can make a meaningful difference in their daily lives.”

Ray-Ban Meta AI glasses combine a lightweight, hands-free design with built-in artificial intelligence to help users complete everyday tasks more independently. Wearers can ask the glasses to describe their surroundings, read printed text, identify objects, and capture photos or videos.

To receive a pair of Ray-Ban Meta AI glasses at the July 27 distribution event, individuals must provide proof of military service, acknowledge legal blindness, and own a compatible smart phone.

A day pass to the ACB Conference and Convention with access to the Exhibit Hall will be available for recipients.

For more details about the Ray-Ban Meta AI glasses distribution, visit https://www.acb.org/glasses.

About the American Council of the Blind

The American Council of the Blind is a national member-driven consumer organization representing Americans who are blind or have low vision. With 65 affiliates, ACB strives to increase independence, security, equality of opportunity, and to improve the quality of life for all people who are blind or have low vision. For more information, visit https://www.acb.org.

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-american-council-of-the-blind-to-distribute-ray-ban-meta-ai-glasses-to-blind-veterans-in-st-louis-on-july-27-302826844.html

SOURCE American Council of the Blind

Continue Reading

Trending